Skip to main content
Delfa

← Trials/Trial dossier/NCT06840054

Not yet recruitingPhase 2

The Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Mild to Moderate Alzheimer's Disease

The Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Mild to Moderate Alzheimer's Disease: A Randomised, Double-Blind, Placebo-Controlled Phase 2 Trial

Asset

Sodium Pentaborate Pentahydrate

Listed sites

0

Recruiting sites

-

Enrollment

30

estimated

Study population

Alzheimer’s disease

Key I/E criteria

•mild-to-moderate AD•MMSE 10-24

Primary endpoint

•ADAS-Cog

Identifiers

Registered as

Org study ID75883
NCT IDNCT06840054

Timeline

Milestones

Study first posted2025-02-21actual
Last update posted2025-02-21actual
Study start2025-05-01estimated
Primary completion2026-01-30estimated
Study completion2026-01-30estimated

Assets

Drug assets

Sodium Pentaborate Pentahydrate

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age55 Years
Maximum age85 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

Age between 55 and 85 years Diagnosis of mild to moderate Alzheimer's disease based on the National Institute on Aging and Alzheimer's Association (NIA-AA) criteria Mini-Mental State Examination (MMSE) score between 10 and 24 Evidence of episodic memory impairment (≥1 standard deviation below age norm) Use of stable doses of Alzheimer's medications

Exclusion criteria

Presence of major neurological or psychiatric disorders Significant amyloid-related imaging abnormalities (ARIA) detected on magnetic resonance imaging (MRI) Recent use of experimental drugs

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Global cognition
1
Function / daily living
1
Other (unclassified)
1

Global cognition

1 endpoint
Secondary/protocol endpoint

Clinical Dementia Rating - Sum of Boxes (CDR-SB)

Time frame:Baseline to month 6

Clinical Dementia Rating-Sum of Boxes (CDR-SB)

descriptive

Function / daily living

1 endpoint
Secondary/protocol endpoint

Alzheimer's Disease Cooperative Study - Activities of Daily Living Scale (ADCS-ADL)

Time frame:Baseline to month 6.

ADCS-Activities of Daily Living (ADCS-ADL)

descriptive

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13)

Time frame:Baseline to month 6

ADAS-Cog

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.